By Dark patches on the skin are among the most common dermatological concerns worldwide – and among the most frustrating to treat. People spend significant time and money on products that promise to fade them, often with disappointing results, partly because the term “hyperpigmentation” covers several distinct conditions with different causes and different responses to treatment.
Understanding which type of hyperpigmentation you’re dealing with is the essential first step – because the treatment for melasma is different from the treatment for post-inflammatory hyperpigmentation, which is different from age spots. Getting this distinction right saves time, money, and the frustration of applying the wrong product for months without result.
What Hyperpigmentation Is
Hyperpigmentation is the darkening of an area of skin relative to the surrounding skin. It results from excess melanin – the pigment produced by melanocytes – being deposited in the epidermis (superficial layers), dermis (deeper layers), or both.
Melanin production is driven by melanocytes, which respond to several stimuli: UV radiation, hormones (particularly oestrogen and progesterone), inflammation, and various chemical signals. When any of these stimuli are excessive or dysregulated, melanocytes produce more melanin than normal – producing visible darkening.
The depth of melanin determines both the colour and the treatability of hyperpigmentation:
- Epidermal melanin appears brown and responds better to topical treatments
- Dermal melanin appears grey or blue-grey and is significantly more resistant to treatment
- Mixed epidermal-dermal is the most common pattern in melasma – partially responsive to treatment
The Main Types of Hyperpigmentation
Melasma
Melasma is the most common and most discussed form of hyperpigmentation. It produces symmetrical brown or grey-brown patches on the face – most commonly on the cheeks, forehead, upper lip, nose, and chin. It follows a characteristic distribution that reflects its hormonal drivers.
Melasma is predominantly a condition of women (90% of cases), particularly during reproductive years. It’s significantly more common in people with Fitzpatrick skin types III-VI (medium to dark skin tones) – affecting people of Latin American, Asian, Middle Eastern, and African descent at higher rates than those with very fair skin.
What drives melasma:
Sun exposure is the most important trigger and the primary reason melasma persists and recurs. UV radiation directly stimulates melanocyte activity – even brief, cumulative sun exposure maintains and worsens melasma. Visible light (not just UV) also stimulates melanin production, particularly in darker skin tones – a clinically important fact because standard UV-filtering sunscreens don’t block visible light.
Hormonal factors are central. Oestrogen and progesterone upregulate melanocyte-stimulating pathways. Melasma is strongly associated with:
- Pregnancy (sometimes called “the mask of pregnancy” or chloasma)
- Combined oral contraceptive pill and hormonal IUDs
- Hormone replacement therapy
The hormonal connection explains why melasma often first appears or worsens during pregnancy and may fade after delivery (though it often doesn’t resolve completely).
Genetics play a significant role – family history of melasma is present in approximately 40-50% of cases.
Heat is an independent trigger – infrared radiation from heat stimulates melanocytes. This is why melasma can worsen near stoves, in hot climates, or from activities generating facial heat.
Thyroid disease is associated with melasma – thyroid hormones affect melanocyte function. Thyroid function testing is appropriate in melasma patients with other thyroid symptoms.
Post-Inflammatory Hyperpigmentation (PIH)
Post-inflammatory hyperpigmentation is darkening that occurs at sites of previous skin inflammation or injury. It’s not a primary condition but a consequence of another process: acne, eczema, psoriasis, insect bites, burns, cuts, or any other source of skin injury or inflammation.
The mechanism: inflammation triggers keratinocytes (skin cells) to release signals that stimulate melanocyte activity, depositing excess melanin at the site of injury. In darker skin tones, this inflammatory melanocyte stimulation is more pronounced – which is why PIH is more severe and more persistent in people with skin types IV-VI.
PIH is the most common form of hyperpigmentation globally – affecting people of all skin tones but disproportionately those with darker complexions. For many people with darker skin, PIH from acne is more distressing than the acne itself.
Solar Lentigines (Age Spots, Liver Spots)
Solar lentigines – commonly called age spots or liver spots – are flat, well-defined brown spots that develop on sun-exposed areas (face, hands, forearms, shoulders) after years of cumulative UV exposure. They’re not related to liver function; the “liver spot” name is a misnomer.
They develop through cumulative melanocyte activation from decades of UV exposure. They become more common with age and with lighter skin types – the opposite pattern from melasma, which is more common in darker skin.
Ephelides (Freckles)
Freckles are small, flat, light-brown spots that appear primarily in fair-skinned individuals with MC1R gene variants. Unlike solar lentigines, freckles fade in winter (when UV exposure is lower) and darken in summer – reflecting their direct dependence on ongoing UV stimulation.
Periorbital Hyperpigmentation (Dark Circles)
Dark circles under the eyes have multiple causes – not all of them pigmentation. True pigmentation-related dark circles reflect excess melanin deposition in the periorbital area, more common in darker skin tones and with genetic predisposition. Other causes of dark circles include vascular (showing through thin skin), structural (shadowing from tear troughs and fat loss), and dehydration – these don’t respond to pigmentation treatments.
Assessment: Fitzpatrick Skin Type and Wood’s Lamp
Fitzpatrick skin type (I-VI) describes skin’s response to UV radiation and is clinically relevant to hyperpigmentation assessment:
- Types I-II (very fair, burns easily, never tans): more prone to freckles and solar lentigines
- Types III-IV (medium, tans moderately): melasma most common in this range
- Types V-VI (dark brown to black): PIH most severe; melasma also common; treatments carry higher risk of PIH from irritation
Wood’s lamp examination (UV light examination) helps assess melanin depth:
- Epidermal melanin: appears more prominent under Wood’s lamp (enhanced contrast)
- Dermal melanin: doesn’t enhance under Wood’s lamp
- Mixed: partial enhancement
This guides treatment expectations – epidermal-predominant melasma responds better to topical treatment than dermal-predominant.
Treatment: What the Evidence Shows
Sun Protection – The Non-Negotiable Foundation
No hyperpigmentation treatment works adequately without rigorous sun protection – and this is where most treatment failures begin. UV and visible light continuously restimulate melanocytes, maintaining and worsening pigmentation regardless of what topical treatments are applied.
Broad-spectrum sunscreen SPF 30 or higher: Applied every morning, reapplied every 2 hours with sun exposure. Both UVA and UVB protection required – UVA penetrates glass and causes pigmentation without visible burning.
Iron oxide-containing sunscreens or tinted sunscreens: Particularly important for melasma in darker skin tones. Iron oxides block visible light, which standard UV filters don’t – a clinically meaningful distinction for melasma management.
Physical sun avoidance and protective clothing: Wide-brimmed hats, sun-protective clothing, seeking shade – particularly important between 10am and 4pm.
Without consistent sun protection, other treatments have limited and temporary effect.
Topical Treatments
Hydroquinone – the most studied skin-lightening agent. Inhibits tyrosinase, the key enzyme in melanin synthesis. Available at 2% OTC in many countries and 4% by prescription. Most effective topical agent for melasma and PIH in clinical trials. Should be used cyclically (3-6 months on, then off) due to risk of ochronosis (paradoxical darkening) with very prolonged use. Not available OTC in EU and some other regions due to regulatory decisions; available by prescription.
Azelaic acid (15-20%): Anti-inflammatory and tyrosinase inhibitor. Effective for melasma and PIH. Well-tolerated in darker skin tones with lower irritation risk than retinoids. Available OTC at 10% in many countries; prescription at 15-20%.
Kojic acid: Derived from fungi, inhibits tyrosinase. Widely used in cosmeceutical products globally. Effective but can cause contact dermatitis. Often combined with other agents.
Tranexamic acid: Originally a medication for blood clotting, tranexamic acid has emerged as a significant treatment for melasma – both topically (2-5%) and orally (low dose, 250mg twice daily). Multiple randomised controlled trials support its effectiveness for melasma. Oral tranexamic acid is increasingly used in dermatology practices globally for melasma resistant to topical treatment.
Vitamin C (L-ascorbic acid): Antioxidant that inhibits melanin synthesis. Effective at higher concentrations (10-20%) in stable formulations. Widely available in cosmeceutical products. More modest effect than hydroquinone but well-tolerated and safe for all skin types.
Niacinamide (vitamin B3): Inhibits melanosome transfer from melanocytes to keratinocytes. Anti-inflammatory properties also useful for PIH from acne. Well-tolerated at 4-10%. Widely available OTC. Modest but consistent evidence for hyperpigmentation reduction.
Retinoids (tretinoin, retinol, adapalene): Accelerate skin cell turnover, dispersing melanin more rapidly. Tretinoin (retinoic acid) has strong evidence for melasma when used alongside hydroquinone. The Kligman formula – hydroquinone + tretinoin + mild corticosteroid – remains one of the most effective triple-combination treatments studied. Retinoids increase photosensitivity and can cause irritation – must be used at night with rigorous sun protection.
Arbutin, licorice extract (glabridin), mulberry extract: Plant-derived tyrosinase inhibitors widely used in cosmeceuticals. Modest evidence compared to hydroquinone but suitable for long-term use.
Procedures
Chemical peels: Superficial peels (glycolic acid, salicylic acid, lactic acid, mandelic acid) accelerate exfoliation and improve epidermal-level pigmentation. Multiple sessions needed. In darker skin tones, superficial-to-medium depth peels are safer than deep peels, which risk PIH. Medium and deep peels should be approached with extreme caution in skin types V-VI.
Laser and light treatments: Multiple laser systems are used for hyperpigmentation – Q-switched Nd:YAG, picosecond lasers, fractional lasers, intense pulsed light (IPL). Highly effective for solar lentigines in fair skin. For melasma, results are inconsistent – laser can worsen melasma through heat stimulation and post-treatment PIH, particularly in darker skin. Laser treatment for melasma in darker skin tones requires significant expertise and often produces disappointing results. Q-switched Nd:YAG at low fluence (the “laser toning” technique) has evidence for melasma in Asian skin specifically.
Microneedling: Creates controlled micro-injuries that may improve delivery of topical agents and stimulate skin remodelling. Some evidence for PIH and melasma improvement. Generally safer in darker skin than ablative laser.
Treatment Approach by Type
| Type | First Line | Avoid |
|---|---|---|
| Melasma | Sun protection + hydroquinone or tranexamic acid + azelaic acid | High-energy laser in darker skin; prolonged hydroquinone |
| PIH from acne | Treat underlying acne + azelaic acid or niacinamide + sun protection | Aggressive peels in darker skin |
| Solar lentigines | Q-switched laser, IPL, cryotherapy (fair skin); topicals for darker skin | Aggressive treatment in darker skin without expertise |
| Freckles | Sun protection (prevents new ones); laser for existing ones in fair skin | N/A |
Frequently Asked Questions
Why is hyperpigmentation harder to treat in darker skin tones? Two reasons. First, darker skin has more active melanocytes that respond more dramatically to inflammatory and UV stimuli – producing more pronounced PIH and melasma. Second, many aggressive treatments (laser, strong chemical peels) can themselves cause PIH in darker skin by triggering the same inflammatory melanocyte-stimulation pathway they’re trying to treat. This requires more conservative approaches and greater expertise from practitioners.
How long does treatment take to work? Realistic timelines: topical treatments for melasma and PIH typically require 8-12 weeks of consistent use before significant improvement is visible – skin cell turnover takes time. Full results from topical treatment may take 3-6 months. Solar lentigines respond faster to laser treatment (1-3 sessions for most) than to topical agents.
Can hyperpigmentation be permanently cured? For most forms – no. Solar lentigines can be effectively cleared with laser treatment and don’t typically recur if sun protection is maintained. Melasma is a chronic condition that recurs with sun exposure and hormonal triggers – it requires ongoing maintenance treatment and strict sun protection rather than a one-time cure. PIH resolves over time once the underlying inflammation is controlled but the timeline varies from months to years.
Are skin lightening creams safe? Reputable skin-lightening ingredients (hydroquinone at appropriate concentrations, azelaic acid, kojic acid, tranexamic acid, vitamin C, niacinamide) have well-characterised safety profiles when used as directed. The concern is with unregulated or counterfeit products – particularly those sold illegally containing mercury or very high concentrations of hydroquinone (above 4%) without medical supervision. Mercury-containing skin lightening products are illegal in most countries but remain in circulation in informal markets and cause serious toxicity.
Does diet affect skin pigmentation? Dietary antioxidants (vitamin C, polyphenols) may modestly support skin health and reduce oxidative stress that can worsen pigmentation. Adequate sun protection and topical treatment have far larger effects than diet on hyperpigmentation. Some evidence suggests that certain dietary compounds (e.g. polypodium leucotomos extract, an oral antioxidant from a fern plant) have modest photoprotective and anti-melasma effects as supplements – not substitutes for sunscreen.
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Persistent or worsening hyperpigmentation, particularly when accompanied by other skin changes, should be evaluated by a qualified dermatologist. Treatment approaches should be individualised based on skin type, pigmentation pattern, and medical history.
References
- Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell & Melanoma Research. 2018;31(4):461-465. https://doi.org/10.1111/pcmr.12684
- Rodrigues M, Ayala-Cortés AS, Rodríguez-Arámbula A, et al. Interpretation of the literature on melasma. JAMA Dermatology. 2020;156(12):1367-1374. https://doi.org/10.1001/jamadermatol.2020.2489
- Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatology and Therapy. 2017;7(3):305-318. https://doi.org/10.1007/s13555-017-0194-1
- Sheth VM, Pandya AG. Melasma: a comprehensive update. Journal of the American Academy of Dermatology. 2011;65(4):689-697. https://doi.org/10.1016/j.jaad.2010.12.044
- Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. Journal of Clinical and Aesthetic Dermatology. 2010;3(7):20-31.
- Adalatkhah H, Sadeghi-Bazargani H. The association between melasma and postinflammatory hyperpigmentation in acne patients. Journal of Cosmetics, Dermatological Sciences and Applications. 2012;2(4):230-234.
- World Health Organization (WHO). Mercury in skin lightening products. https://www.who.int/news-room/fact-sheets/detail/mercury-in-skin-lightening-products
- Tam KW, Wu CC, Huang TW, et al. Tranexamic acid for melasma: a systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2020;83(6):1756-1758. https://doi.org/10.1016/j.jaad.2020.04.108
- Hexsel D, Rodrigues TC, Dal’Forno T, Zechmeister-Prado D, Lima MM. Melasma and pregnancy in southern Brazil. Journal of the European Academy of Dermatology and Venereology. 2009;23(3):367-368. https://doi.org/10.1111/j.1468-3083.2008.02913.x
- British Association of Dermatologists. Melasma patient information leaflet. https://www.bad.org.uk/patient-information-leaflets/melasma/